Micro RNA: New aspect in pathobiology of preeclampsia?

Egyptian Journal of Medical Human Genetics

Volumn 13, Issue 2, 2012, Pages 127-131

  Harapan, Harapan ^a   Andalas, Mohd ^a   Mudhakir, Diky ^b   Pedroza, Natalia C ^c   Laddha, Saurabh V ^d   Anand, Jay R ^e  

^a SYIAH KUALA UNIVERSITY   (Indonesia)

^b BANDUNG INSTITUTE OF TECHNOLOGY   (Indonesia)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^d CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^e NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

MicroRNA; MiRNA; Preeclampsia; Preeclampsia pathogenesis

Indexed keywords

ANGIOPOIETIN RECEPTOR; ARGONAUTE PROTEIN; CAENORHABDITIS ELEGANS PROTEIN; LIN 4 PROTEIN; MESSENGER RNA; MICRORNA; PLACENTAL GROWTH FACTOR; RNA POLYMERASE II; RNA PRECURSOR; TIE 1 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BIOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; DISEASE SEVERITY; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; INTRON; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; RNA STRUCTURE; SIGNAL TRANSDUCTION;

EID: 84877060932     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2011.09.002     Document Type: Review

References (54)

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
2. Am. Coll. Obstet. Gynecol. Comm. Obstet. Pract. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99:159-167.
3. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1e22.
4. WHO. 2005. World health report: Make every mother and child count. Geneva: World Health Organization.
5. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009, 33:130e7.
6. Koga K., Osuga Y., Tajima T., Hirota Y., Igarashi T., Fujii T., Yano T., Taketani Y. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2010, 94(1):305-308.
7. Matsuo K., Kooshesh S., Dinc M., Sun C.C., Kimura T., Baschat A.A. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 2007, 24:257-266.
8. Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of Preeclampsia. Annu Rev Pathol Mech Dis 2010, 5:173-192.
9. Cerdeira A.S., Karumanchi S.A. Biomarkers in Preeclampsia. Biomarkers in Kidney Disease 2010, 385-426. Elsevier Inc.
10. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
11. Bushati N., Cohen S.M. MicroRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
12. Kloosterman W.P., Plasterk R.H.A. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11:441-450.
13. Sun W., Li Y.S.J., Huang H.D., Shyy J Y.-J., Chien S. microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng 2010, 12:1-27.
14. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 9:92-105.
15. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
16. Poy M.N., Eliasson L., Krutzfeldt J., Kuwajima S., Ma X., Macdonald P.E., Pfeffer S., Tuschl T., Rajewsky N., Rorsman P., Stoffel M. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432:226-230.
17. Jin P., Alisch R.S., Warren S.T. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 2004, 6:1048-1053.
18. Pellish R.S., Nasir A., Ramratnam B., Moss S.F. Review article: RNA interference - potential therapeutic applications for the gastroenterologist. Aliment Pharmacol Ther 2008, 27:715-723.
19. Garofalo M., Croce C.M. microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 2011, 51:25-43.
20. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nature Reviews Cancer 2010, 10:389-402.
21. Pineles B.L., Romero R., Montenegro D., Tarca A.L., Han Y.M., Kim Y.M., Draghici S., Espinoza J., Kusanovic J.P., Mittal P., Hassan S.S., Kim C.J. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 2007, 196:261.e1-261.e6.
22. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Gene. 2010, AOP. 10.1038/nrg284.
23. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136:642-655.
24. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem 2010, 79:351-379.
25. Fabian M.R., Sundermeier T.R., Sonenberg N. Understanding How miRNAs Post-Transcriptionally Regulate Gene Expression. miRNA Regulation of the Translational Machinery Progress in Molecular and Subcellular Biology 50 2010, 1-20. Springer-Verlag, Berlin Heidelberg. R.E. Rhoads (Ed.).
26. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
27. Gu S., Kay M.A. How do miRNAs mediate translational repression?. Silence 2010, 1:11-15.
28. Nilsen T.W. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends in Genetics 2007, 23:243-249.
29. Ender C., Meister G. Argonaute proteins at a glance. Cell Sci 2010, 123:1819-1823.
30. Roberts J.M., Hubel C.A. The two stage model of preeclampsia: variations on the theme. Placenta 2009, 30(23):S32-S37.
31. Mellembakken J.R., Aukrust P., Olafsen M.K., Ueland T., Hestdal K., Videm V. Activation of leukocytes during the uteroplacental passage in preeclampsia. Hypertension 2002, 39:155-160.
32. Mutter W.P., Karumanchi S.A. Molecular mechanisms of preeclampsia. Microvascular Research 2008, 75:1-8.
33. Maynard S.E., Epstein F.H., Karumanchi S.A. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008, 59:61-78.
34. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., Schisterman E.F., Thadhani R., Sachs B.P., Epstein F.H., Sibai B.M., Sukhatme V.P., Karumanchi S.A. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672e83.
35. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P., Sibai B.M., Epstein F.H., Romero R., Thadhani R., Karumanchi S.A. CPEP study group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992e1005.
36. Shibata E., Rajakumar A., Powers R.W., Larkin R.W., Gilmour C., Bodnar L.M., Crombleholme W.R., Ness R.B., Roberts J.M., Hubel C.A. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005, 90:4895-4903.
37. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., Bdolah Y., Lim K.H., Yuan H.T., Libermann T.A., Stillman I.E., Roberts D., D'Amore P.A., Epstein F.H., Sellke F.W., Romero R., Sukhatme V.P., Letarte M., Karumanchi S.A. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
38. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., Libermann T.A., Morgan J.P., Sellke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P., Karumanchi S.A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 2003, 111:649-658.
39. Kim Y.M., Romero R., Oh S.Y., Kim C.J., Kilburn B.A., Armant R., Nien J.K., Gomez R., Mazor M., Saito S., Abrahams V.M., Mor G. Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia?. Am J Obstet Gynecol 2005, 193:921-927.
40. Yang W.J., Yang D.D., Na S., Sandusky G.E., Zhang Q., Zhao G. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005, 280:9330-9335.
41. Fei L.P., Li H.Y., Sha H., Liu L., Li Z.J., Yi H.Y. The expression of microRNA in placenca from severe preeclampsia patients. Chinese Journal of Practical Gynecology and Obstetrics 2009, 25(12):911-914.
42. Hu Y., Li P., Hao S., Liu L., Zhao J., Hou Y. Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin Chem Lab Med 2009, 47(8):923-929.
43. Zhou Y., McMaster M., Woo K., Janatpour M., Perry J., Karpanen T., Alitalo K., Damsky C., Fisher S.J. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002, 160:1405-1423.
44. Lam C., Lim K.H., Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46:1077-1085.
45. Mo F.E., Muntean A.G., Chen C.C., Stolz D.B., Watkins S.C., Lau L.F. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002, 22:8709-8720.
46. Gellhaus A., Schmidt M., Dunk C., Lye S.J., Kimmig R., Winterhager E. Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. Mol Hum Reprod 2006, 12:389-399.
47. Zhang Y., Diao Z., Su L., Sun H., Li R., Cui H., Hu Y. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol 2010, 202:466.e1-466.e7.
48. Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods K., Mercatanti A., Hammond S., Rainaldi G. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006, 108:3068-3071.
49. Matsui J., Wakabayashi T., Asada M., Yoshimatsu K., Okada M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem 2004, 279:18600-18607.
50. Zhu X.-M., Han T., Sargent I.L., Yin G.-W., Yao Y.-Q. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol 2009, 200:661.e1-661.e7.
51. Fasanaro P., D'Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G., Capogrossi M.C., Martelli F. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine-kinase ligand Ephrin-A3. J Biol Chem 2008, 283:15878-15883.
52. Enquobahrie D.A., Abetew D.F., Sorensen T.K., Willoughby D., Chidambaram K., Williams M.A. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2011, 204(2):178.e12-178.e21.
53. Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyak N., Lee K.H., Ma Q., Kang P.M., Golub T.R., Pu W.T. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009, 29:2193-2204.
54. 2+ mobilization through angiotensin receptor activation. Circulation 2004, 110:1612-1619.